alexa The Development of Cold-type Autoimmune Hemolytic Anemi
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

The Development of Cold-type Autoimmune Hemolytic Anemia during Peginterferon alfa-2a plus Ribavirin Treatment in Chronic Hepatitis C Patient: a Case Report

Putut Bayupurnama1* and Kartika Widayati Taroeno-Hariadi2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
2Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Corresponding Author : Dr. Putut Bayupurnama
Division of Gastroenterology and Hepatology
Department of Internal Medicine, Faculty of Medicine
Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
E-mail: [email protected]
Received June 28, 2012; Accepted July 17, 2012; Published July 19, 2012
Citation: Bayupurnama P, Taroeno-Hariadi KW (2012) The Development of Coldtype Autoimmune Hemolytic Anemia during Peginterferon alfa-2a plus Ribavirin Treatment in Chronic Hepatitis C Patient: a Case Report. J Clin Case Rep 2:173. doi:10.4172/2165-7920.1000173
Copyright: © 2012 Bayupurnama P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Peginterferon-alfa 2a or alfa 2b plus ribavirin is the treatment of choice in chronic hepatitis C. Severe adverse effects may compromise efficacy of this regiment. There are few reports of warm autoimmune hemolytic anemia following interferon-alfa or peginterferon-alfa2b plus ribavirin treatment. This present report discusses autoimmune hemolytic anemia which developed during peginterferon alfa-2a/ribavirin treatment and caused dose cessation. The anemia was improved with discontinuation of peginterferon-alfa 2a/ribavirin and adminstration of erythropoietin stimulating agent.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords